Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 3rd Annual H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Ron Bentsur, the company's Chairman and CEO, will deliver a presentation on May 20th, 2025, from 10:30 to 11:00 a.m. ET. The presentation will be accessible via webcast for interested investors and stakeholders.
Details
News Market Reaction – NVCT
The recorded move for NVCT in the trading session of this news was +10.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference.
| Event | 3rd Annual H.C. Wainwright BioConnect Investor Conference |
| Date | May 20th, 2025 |
| Time | 10:30 – 11:00 a.m. ET |
| Link | Nuvectis Pharma Presentation Webcast Link |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.